| |
Tofacitinib 5 mg BID
|
Tofacitinib 10 mg BID
|
Total
|
|---|
|
(n = 381)
|
(n = 105)
|
(n = 486)
|
|---|
|
Female, n (%)
|
318 (83.5)
|
86 (81.9)
|
404 (83.1)
|
|
Age in years, mean (SD)
|
53.5 (11.2)
|
49.3 (11.7)
|
52.6 (11.4)
|
|
Disease duration in years, mean (range)
|
7.8 (0.4–38.0)
|
6.1 (0.4–45.0)
|
7.4 (0.4–45.0)
|
|
Tender joint counta, n
|
16.1
|
17.0
|
16.3
|
|
Swollen joint counta, n
|
13.4
|
14.3
|
13.6
|
|
HAQ-DIb score
|
1.23
|
1.22
|
1.23
|
|
DAS28-4(ESR) score
|
6.0
|
6.1
|
6.0
|
|
DAS28-3(CRP) score
|
5.0
|
5.2
|
5.1
|
|
ESR, mm/h
|
50.7
|
47.7
|
50.1
|
|
CRP, mg/L
|
24.1
|
27.4
|
24.9
|
|
Concomitant methotrexate, n (%)
|
196 (51.4)
|
26 (24.8)
|
222 (45.7)
|
|
Concomitant systemic corticosteroids, n (%)
|
256 (67.2)
|
80 (76.2)
|
336 (69.1)
|
- Data are mean values except where indicated. Baseline values were those of the index study
-
aScale 0–68 (tender/painful joints) and 0–66 (swollen joints); higher values indicate greater levels of disease activity
-
bScale: 0–3; higher values indicate reduced physical function
-
BID twice daily, CRP C-reactive protein, DAS Disease Activity Score, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, SD standard deviation
